Modern H1 antihistamines in the treatment of patients with allergic rhinitis and comorbid acute respiratory infections

Close metadata

OBJECTIVE

To evaluate the effect of therapy using modern antihistamines on the condition and severity of symptoms in adult patients with exacerbation of AR caused by plant pollen (seasonal) (SAR) and the development of ARVI.

MATERIAL AND METHODS

An observational study was conducted at the Department of Otorhinolaryngology of the Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation from April to August 2021. Included are patients of both sexes aged 18 to 65 years with a previously (at least 1 year ago) verified diagnosis of mild and moderate acute SAR in the acute stage, who sought medical help for ARVI. All patients were prescribed therapy with the inclusion of a drug belonging to the pharmacological group of antihistamines of the 2nd generation (a course of 14 days). In addition, patients received symptomatic ARVI therapy according to indications, including nasal decongestants (as needed), antipyretic and antitussive drugs.

RESULTS

Based on the data obtained, it was possible to prove that the use of modern antihistamines in patients comorbid with AR and ARVI has a pronounced therapeutic effect. Theoritin provides a therapeutic effect at an early stage in relation to nasal and non-nasal symptoms of SAR/ARVI, and also quickly improves the quality of life of patients, which makes its use promising for the treatment of ARVI against the background of AR. The drug has an antihistamine activity comparable to cetirizine and surpasses it in its ability to suppress an allergic inflammatory reaction, for example on the skin, as well as in the duration of preservation of the antihistamine effect.

CONCLUSION

The presented results indicate the effectiveness of theoritin and cetirizine in the treatment of patients with seasonal exacerbation of allergic rhinitis, comorbid for acute respiratory viral infections.

Keywords:

allergic rhinitis

acute respiratory viral diseases

H1 antihistamines

cetirizine

theoritin

Authors:

Ovchinnikov A.Yu.

Evdokimov Moscow State University of Medicine and Dentistry

Miroshnichenko N.A.

Evdokimov Moscow State University of Medicine and Dentistry

Nikolaeva Yu.O.

Evdokimov Moscow State University of Medicine and Dentistry

Received:

06.05.2022

Accepted:

25.05.2022

List of references:

Nenasheva NM, Shartanova NV, Ovchinnikov AYu, Osipova GL, Zhestkov AV, Pavlova NV. Seasonal allergic rhinitis and its control with antihistamines in outpatient practice. Rossijskij allergologicheskij zhurnal. 2020;17(2):44-52. (In Russ.). https://doi.org/10.36691/RJA1370
Ahmad N, Zacharek MA. Allergic rhinitis and rhinosinusitis. Otolaryngologic Clinics of North America. 2008;41(2):267-281. https://doi.org/10.1016/j.otc.2007.11.010
Cirillo I, Marseglia G, Klersy C, Ciprandi G. Allergic patients have more numerous and prolonged respiratory infections than nonallergic subjects. Allergy. 2007;62(9):1087-1090. https://doi.org/10.1111/j.1398-9995.2007.01401.x
Rantala A, Jaakkola JJ, Jaakkola MS. Respiratory infections in adults with atopic disease and IgE antibodies to common aeroallergens. PLoS One. 2013;8(7):e68582. https://doi.org/10.1371/journal.pone.0068582
De Corso E, Lucidi D, Cantone E, Ottaviano G, Di Cesare T, Seccia V, Paludetti G, Galli J. Clinical Evidence and Biomarkers Linking Allergy and Acute or Chronic Rhinosinusitis in Children: A Systematic Review. Current Allergy and Asthma Reports. 2020;20(11):68. https://doi.org/10.1007/s11882-020-00967-9
Jeon YJ, Lim JH, An S, Jo A, Han DH, Won TB, Kim DY, Rhee CS, Kim HJ. Type III interferons are critical host factors that determine susceptibility to Influenza A viral infection in allergic nasal mucosa. Clinical and Experimental Allergy. 2018;48(3): 253-265. https://doi.org/10.1111/cea.13082
Kim H, Kwon GE, Kim YH, Callaway Z, Han YS, Seo JJ, Jiao F, Kim CK. Comparison of serum eosinophil-derived neurotoxin levels between wheezing and non-wheezing groups in children with respiratory tract infection. The Journal of Asthma. 2020;57(11): 1211-1215. https://doi.org/10.1080/02770903.2019.1642349
Noah TL, Becker S. Chemokines in nasal secretions of normal adults experimentally infected with respiratory syncytial virus. Clinical Immunology. 2000;97(1):43-49. https://doi.org/10.1006/clim.2000.4914
Skoner DP, Gentile DA, Fireman P, Cordoro K, Doyle WJ. Urinary histamine metabolite elevations during experimental influenza infection. Annals of Allergy, Asthma and Immunology. 2001; 87(4):303-306. https://doi.org/10.1016/s1081-1206(10)62244-2
Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nature Reviews. Immunology. 2021;21(11):739-751. https://doi.org/10.1038/s41577-021-00538-7
Hoffmans R, Wagemakers A, van Drunen C, Hellings P, Fokkens W. Acute and chronic rhinosinusitis and allergic rhinitis in relation to comorbidity, ethnicity and environment. PLoS One. 2018;13(2):e0192330. https://doi.org/10.1371/journal.pone.0192330
Nosulya EV, Kim IA, Luchsheva YuV, Izotova GN. Comorbidity of allergic rhinitis: relevance of antihistamine therapy in daily practice. The Russian Journal of Preventive Medicine. 2019;22(4):124-128. (In Russ.). https://doi.org/10.17116/profmed201922041124
Mlynski G, Beule A. Diagnostic methods of nasal respiratory function. HNO. 2008;56(1):81-99. https://doi.org/10.1007/s00106-007-1655-0
Ovchinnikov AYu, Miroshnichenko NA, Dzhimsheleishvili NP, Simsova VA, Nikolaeva YuO. Elimination agents as part of combination therapy of chronic rhinosinusitis associated with allergic rhinitis. Medical Council. 2021;6:100-104. (In Russ.). https://doi.org/10.21518/2079-701X-2021-6-100-104
Głobińska A, Pawełczyk M, Piechota-Polańczyk A, Olszewska-Ziąber A, Moskwa S, Mikołajczyk A, Jabłońska A, Zakrzewski PK, Brauncajs M, Jarzębska M, Taka S, Papadopoulos NG, Kowalski ML. Impaired virus replication and decreased innate immune responses to viral infections in nasal epithelial cells from patients with allergic rhinitis. Clinical and Experimental Immunology. 2017;187(1):100-112. https://doi.org/10.1111/cei.12869
Gushchin IS, Kryshen KL, Bondarenko AB. Anti-inflammatory activity of the antiallergic drug 7-[4-(4-benzhydrylpiperazinyl-1)butyl]-3-methylxanthine succinate (theoritin). Rossijskij allergologicheskij zhurnal. 2021;18(2):20-31. (In Russ.). https://doi.org/10.36691/RJA1445
Ovchinnikov AYu, Miroshnichenko NA, Nikolaeva YuO. Arguments in favor of the use of modern H1-blockers of histamine receptors for the treatment of patients with allergic rhinitis occurring against the background of ARVI. Rossijskaya otorinolaringologiya. 2021;20(6):116-126. (In Russ.). https://doi.org/10.18692/1810-4800-2021-6-125-135
Glushkov RG, Yuzhakov SD, Alekseev MV, Fominova OS, Shorr VA, Zhdanov GF, Dolginova EM, Sazonova NM, Andreeva NI, Salin EN, Asnina VV. A new group of derivatives of 1- and 7-[ω-(benzhydryl-1) alkyl]-3-methylxanthines with antihistamine activity. Khimiko-farmatsevticheskij zhurnal. 2011;45(1):3-13. (In Russ.).
Ovchinnikov AYu, Miroshnichenko NA, Khon EM, Dzhimshelejshvili NP, Simsova VA, Nikolaeva YuO. From clinical recommendations to practice. Clinical experience in the treatment of patients with allergic rhinitis. Medical Council. 2021;18:62-67. (In Russ.). https://doi.org/10.21518/2079-701X-2021-18-62-67

Close metadata